Calico (company)

Calico (company)
Name	Calico
Type	Subsidiary
Industry	Biotechnology
Founded	2013
Founder	Arthur D. Levinson
Headquarters	South San Francisco, California, United States
Key people	Arthur D. Levinson (CEO)
Parent	Alphabet Inc.

Calico (company) is an American biotechnology research and development company focused on aging and age-related diseases. Founded in 2013, it operates as a subsidiary of Alphabet Inc. and engages with scientific institutions, pharmaceutical firms, and academic laboratories to pursue translational research in longevity and geroscience. The organization combines approaches from molecular biology, genomics, and computational biology to investigate mechanisms underlying senescence and chronic disease.

History

Calico was announced in 2013 by Larry Page and launched with leadership from Arthur D. Levinson, drawing attention alongside contemporaneous initiatives from NIH programs and private ventures such as Human Longevity, Inc. and Verily. Early milestones included strategic hires from institutions like Genentech, Stanford University, and Harvard Medical School, and the formation of a landmark partnership with AbbVie in 2014. Throughout the 2010s the firm expanded laboratory facilities in San Francisco and engaged with research networks including Broad Institute, Salk Institute, and Massachusetts Institute of Technology to pursue basic and translational projects. Calico’s trajectory paralleled wider trends in biotechnology investment involving firms such as Google Ventures and collaborations reminiscent of earlier public–private models exemplified by Howard Hughes Medical Institute and Salk Institute agreements.

Mission and Research Focus

Calico’s stated mission centers on understanding the biology of aging and developing interventions to target age-related diseases, aligning with the scientific agendas of Gerontology Research Group, Buck Institute for Research on Aging, and the conceptual frameworks promoted in literature by researchers like Aubrey de Grey and Leonard Hayflick. The company emphasizes studying cellular senescence, proteostasis, telomere dynamics, mitochondrial dysfunction, and DNA damage responses, drawing on methods employed at Cold Spring Harbor Laboratory, Max Planck Institute for Biology of Ageing, and Scripps Research. Its translational focus connects basic discoveries to therapeutic strategies in domains addressed by Food and Drug Administration regulatory pathways and clinical trial networks affiliated with National Institute on Aging consortia.

Research and Development Programs

Calico’s R&D portfolios have encompassed projects in genomics, proteomics, small-molecule therapeutics, and biologics, leveraging technologies from CRISPR-Cas9 platforms developed at University of California, Berkeley and Broad Institute, as well as single-cell sequencing techniques popularized at Broad Institute and Sanger Institute. Research programs have targeted neurodegeneration pathways implicated in Alzheimer's disease and Parkinson's disease, metabolic regulation related to Type 2 diabetes mellitus, and pathways shared with oncology research at institutions like Dana-Farber Cancer Institute. The company has reported exploratory work on model organisms such as Caenorhabditis elegans, Drosophila melanogaster, and murine models used at Jackson Laboratory, integrating computational analysis inspired by efforts at DeepMind and bioinformatics groups at European Bioinformatics Institute.

Partnerships and Collaborations

Calico established major collaborations, most notably a multi-year partnership with AbbVie to advance drug discovery and development, and research alliances with academic centers including Buck Institute for Research on Aging, Stanford University School of Medicine, and Massachusetts General Hospital. It has engaged with consortia and public initiatives such as Allen Institute for Brain Science datasets and shared resources from NIH-funded programs, while interfacing with industry players like Amgen and contract research organizations modelled after Charles River Laboratories. Collaborations extended to computational partners and data initiatives inspired by Google Research and DeepMind to apply machine learning to biological datasets.

Funding and Corporate Structure

Calico incorporated as a subsidiary under Alphabet Inc. with initial funding from Google leadership and subsequent resource allocations managed within Alphabet’s corporate structure alongside subsidiaries like Verily and GV (company). Its financial model combined internal capital from Alphabet with milestone-based cost-sharing in alliances such as the agreement with AbbVie, and it participated in collaborative grant-style projects resonant with financing mechanisms used by Howard Hughes Medical Institute and philanthropic funders like Bill & Melinda Gates Foundation. Governance featured scientific advisory input from figures associated with Rockefeller University, Harvard Medical School, and industry leaders from Genentech and Amgen.

Controversies and Criticism

Calico has faced scrutiny over secrecy and transparency practices reminiscent of debates around private-sector biomedical research involving entities like Theranos and data-sharing controversies linked to Google Health. Critics in academic circles at institutions such as University of California, San Francisco and Yale School of Medicine questioned publication rates and openness relative to expectations set by public research bodies like National Institutes of Health. Ethical discussions invoked comparisons to commercialization and access debates involving Biogen and intellectual property practices observed in partnerships across the biotechnology sector, while commentators in media outlets referencing The New York Times and The Wall Street Journal critiqued timelines and measurable outcomes in longevity research.

Category:Biotechnology companies of the United States Category:Companies based in San Mateo County, California